Mediastinal staging for non-small cell lung cancer.

Area of Science:

• Oncology
• Pulmonology
• Diagnostic Imaging

Background:

• Mediastinal lymph node staging is critical for lung cancer treatment planning, especially in potentially curable patients.
• Accurate staging aims to precisely identify malignancy in mediastinal lymph nodes, balancing diagnostic accuracy with the risks of tissue sampling.

Purpose of the Study:

• To review current international guidelines and recent studies on mediastinal lymph node staging in lung cancer.
• To provide an overview of diagnostic modalities and their accuracy in assessing mediastinal involvement.

Main Methods:

• Computed tomography (CT) and positron emission tomography (PET) are primary imaging tools.
• Endosonographic techniques, including endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound-guided fine needle aspiration (EUS-FNA), are used for tissue confirmation.
• Surgical techniques like video-assisted cervical mediastinoscopy (VACM) and mediastinoscopic lymphadenectomy (VAMLA) are employed in selected cases.

Main Results:

• PET-CT can be sufficient when no mediastinal abnormalities are present and the risk of N2 disease is low.
• Positive endosonography results generally do not require further confirmation.
• Negative results from endosonography may necessitate surgical staging, particularly with new minimally invasive techniques.
• PET-CT and endosonography have limitations in mediastinal restaging, with higher false positive and false negative rates requiring histological confirmation.

Conclusions:

• Mediastinal staging for lung cancer involves a combination of imaging and invasive techniques.
• Endosonography and advanced surgical methods enhance the accuracy of staging, particularly when initial imaging is inconclusive.
• Histological confirmation remains crucial for definitive staging, especially in cases with negative imaging or restaging scenarios.